Steven Cohen Supernus Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $221,460 - $288,435	8,521 Added 6.67%	136,342 $3.65 Million
Q1 2024 May 15, 2024	BUY	$27.11 - $35.17 $3.47 Million - $4.5 Million	127,821 New	127,821 $4.36 Million
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $26,372 - $31,732	755 New	755 $27,000
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $5.92 Million - $8.63 Million	-346,666 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $5.01 Million - $8.56 Million	346,666 New	346,666 $6.24 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.92B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.